New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated May 13, 2026 16:03 UTC